Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

26223 reported adverse events

Drugs of this class: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE EMTRICITABINE AND TENOFOVIR ALAFENAMIDE EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE TRUVADA

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

#	Side effect	Count
0	PAIN	1912
1	ANXIETY	1898
2	EMOTIONAL DISTRESS	1672
3	ECONOMIC PROBLEM	1656
4	ANHEDONIA	1565
5	FOETAL EXPOSURE DURING PREGNANCY	1178
6	DRUG INTERACTION	1083
7	DIARRHOEA	967
8	NAUSEA	944
9	RENAL FAILURE	870

See all common reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	CLOACAL EXSTROPHY	24	0.5581
1	ACUTE HIV INFECTION	75	0.5137
2	BLADDER AGENESIS	25	0.3906
3	HYPERANDROGENISM	21	0.3500
4	SPINOCEREBELLAR DISORDER	13	0.3421
5	FEAR-RELATED AVOIDANCE OF ACTIVITIES	20	0.3226
6	AIDS ENCEPHALOPATHY	18	0.3000
7	CSF VIRUS IDENTIFIED	18	0.2903
8	GASTROINTESTINAL DISORDER CONGENITAL	21	0.2727
9	AIDS DEMENTIA COMPLEX	16	0.2623

See all enriched reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]